- Price
- $2.98
- Day
- +6.05%
- Mkt Cap
- $538.24M
- 52W Range
- $2.67 – $6.94
- Volume
- 3.13M
- Beta
- 2.31
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease (WD).
Read full article
Amova Asset Management Americas Inc. lessened its position in Prime Medicine, Inc. (NASDAQ: PRME) by 9.4% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,940,793 shares of the company's stock after selling 304,713 shares during the quarter. Amova Asset Management Americas Inc.
Read full article